Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Seagen Inc.
Seagen Inc. News
Seagen Inc. Quantitative Score
About Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Seagen Inc. Earnings & Revenue
Seagen Inc. Financials
Table Compare
Compare SGEN metrics with: | |||
|---|---|---|---|
Earnings & Growth | SGEN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SGEN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SGEN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SGEN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Seagen Inc. Income
Seagen Inc. Balance Sheet
Seagen Inc. Cash Flow
Seagen Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Sell |
| Return on Assets | Neutral |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Seagen Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Seagen Inc. Executives
| Name | Role |
|---|---|
| Mr. David R. Epstein B.Sc., M.B.A. | Chief Executive Officer & Director |
| Mr. Todd E. Simpson | Chief Financial Officer |
| Mr. Charles R. Romp | Executive Vice President of Commercial U.S. |
| Dr. Vaughn B. Himes Ph.D. | Chief Technical Officer |
| Peggy Pinkston | Senior Vice President of Investor Relations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. David R. Epstein B.Sc., M.B.A. | Chief Executive Officer & Director | Male | 1962 | 1.39M |
| Mr. Todd E. Simpson | Chief Financial Officer | Male | 1961 | 1.26M |
| Mr. Charles R. Romp | Executive Vice President of Commercial U.S. | Male | 1968 | 1.08M |
| Dr. Vaughn B. Himes Ph.D. | Chief Technical Officer | 1961 | 1.08M | |
| Peggy Pinkston | Senior Vice President of Investor Relations | -- |
Seagen Inc. Insider Trades
| Date | 14 Dec |
| Name | BAKER BROS. ADVISORS LP |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 42977301 |
| Date | 14 Dec |
| Name | BAKER BROS. ADVISORS LP |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 8750 |
| Date | 14 Dec |
| Name | BAKER BROS. ADVISORS LP |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 9260 |
| Date | 14 Dec |
| Name | BAKER BROS. ADVISORS LP |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 9260 |
| Date | 14 Dec |
| Name | BAKER BROS. ADVISORS LP |
| Role | Director |
| Transaction | Disposed |
| Type | D-Return |
| Shares | 9260 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 Dec | BAKER BROS. ADVISORS LP | Director | Disposed | D-Return | 42977301 |
| 14 Dec | BAKER BROS. ADVISORS LP | Director | Disposed | D-Return | 8750 |
| 14 Dec | BAKER BROS. ADVISORS LP | Director | Disposed | D-Return | 9260 |
| 14 Dec | BAKER BROS. ADVISORS LP | Director | Disposed | D-Return | 9260 |
| 14 Dec | BAKER BROS. ADVISORS LP | Director | Disposed | D-Return | 9260 |